Drug Profile
Research programme: microbiome therapeutics - Seres Therapeutics
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Seres Therapeutics
- Developer Massachusetts General Hospital; Seres Therapeutics; University of Pennsylvania
- Class Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases; Metabolic disorders; Metabolic syndrome
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Metabolic-syndrome in USA
- 28 Jun 2020 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA
- 28 Jun 2020 No recent reports of development identified for research development in Metabolic-disorders in USA